




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、 new products.Although the argument isplausible on its face,quantitative evidence onthe robustness of the linkage has been scarce.This paper reports the results of a simple dataanalysis yielding surprising new insights.Profitability and investments in R&D can,in principle,be linked in three rath
2、er differentways.First,successful R&D leads,with longand variable lags,to new products,which,de-pending upon their reception in the market,can add greatly to company profits.The dis-tribution of profit outcomes,as research byHenry Grabowski and John Vernon hasshown,is highly skewed.1A minority o
3、f newproducts confer blockbuster profits,while themajority return less than the capitalized costof R&D,including the cost of failed projects.Second,the profits earned by a companyserve as a source of funds to support R&Dinvestments,and some managers are knownto set R&D budgets using rule
4、s of thumb em-phasizing an indicator of current cash flow orsales.To be sure, as recent experience inbiotechnology shows,funds for R&D can also try were probable exceptions.2Third,manag-ersexpectations of future profit opportuni-ties,which are tempered,inter alia,by contemporary market condition
5、s,can exert a demand-pull influence on R&D investments.3Testing how well these relationships hold for investments in pharmaceutical R&D is rendered difficult by the complex structure of the leading pharmaceutical companies.They operate within a wide variety of fields in addi-tion to ethical
6、drugsfor example,pharmacy benefit management,herbicides and pesti-cides,medical instruments and supplies,prosthetics,hair care products,dental prod-ucts,and nutritional products.The more di-versified companies almost never publish R&D outlay breakdowns subdivided among these fields,and they seld
7、om report their op-erating margin results in enough detail to re-late R&D indices with any precision to meas-ures of profitability.An alternative approach,and the one used here,is to analyze data on R&D investment and profits at the aggregated industry level.©2001 Project HOPEThe People
8、-to-PeopleHealth Foundation,Inc.F.M.Scherer is Aetna Professor of Public Policy Emeritus at Harvard Universitys Kennedy School of Government and a lecturer in public affairs at Princeton University.216H E A L T H A F F A I R S V o l u m e 20,N u m b e r 5 The most closely comparable aggregate time-s
9、eries measure of industry profitability is derived from Census of Manufactures and An-nual Survey of Manufactures data from the U.S.Census Bureau.It is computed as sales less outside materials purchases,payroll outlays,and employee fringe benefitsincluding 4.23percent per yearmuch lower than the 7.5
10、1percent growth rate found for R&D out-lays (Exhibit 2.The disparity of growth rates implies a likely slackening of R&D growth rates in the future. If R&D were covered solely by domestic gross margins,continu-ation of growth trends experienced since 1962SOURCES: Pharmaceutical Research a
11、nd Manufacturers of America, Industry Profile: 1998 (Washington: PhRMA, July 1998; and PhRMA, Annual Survey Report: 198385 (Washington: PhRMA, 1986.NOTE: Outlays have been adjusted for inflation, using the deflator for U.S. gross domestic product, with 1992 as the base year.19621970198019901996217H
12、E A L T H A F F A I R S S e p t e m b e r /O c t o b e r 2001 As in the R&D time series,pharmaceutical industry gross margins exhibit long swings around their exponential time trend. To some extent,coincidence in the timing of the swings can be seen by comparing Exhibits1 and2.However,the relati
13、onships are brought into sharper focus by computing the percent-age deviations of actual R&D outlays and gross margins from their exponential time trend values.6The resulting trend deviation series are juxtaposed in Exhibit3.The degree of coincidence was,at least to this investigator,surprisingl
14、y close.The sim-ple Pearsonian correlation between the two time series is+0.92.Deviations from trend values rise and fall in tandem.The swings are so closely correlated that it would be implau-sible to infer a chain of causation running from R&D to profits,since lags of ten to fif-teen years fro
15、m peak R&D spending to peak profitability for new products are typical.7At two of the three clear turning points,reversals in the R&D spending series precede reversals in the gross margin series by a year or two. This is superficially inconsistent with a hy-pothesis that changes in gross mar
16、gins drive creasingly rich opportunities for profitable new product development.Sensitivity tests revealed that the patterns observed in Exhibit3persist when domestic R&D outlays,a time series available only be-ginning in1970,are substituted for worldwide R&D outlays,and when fringe benefit
17、out-lays,reported by the Census Bureau only be-ginning in1967,are not deducted in calculat-ing gross margins.It is conceivable,as one referee suggested, that the cycles observed here reflect spuri-ously correlated changes in industry aggre-gates,for example, as a result of differences in sample cove
18、rage between the trade associa-tion and Census Bureau universes.To test this possibility, a further analysis correlated trend deviations in variables defined as ratios,with no intermingling of trade association and cen-sus universe data for a given ratio.For R&D, the relevant ratio was worldwide
19、 R&D out-lays,divided by worldwide sales of trade asso-ciation members in any given year.The PhRMA sales variable was not used in the previous analysis.For gross margins, the rele-vant ratio was the gross margin,as defined for218H E A L T H A F F A I R SV o l u m e20,N u m b e r5 SOURCES: Pharma
20、ceutical Research and Manufacturers of America, Industry Profile: 1998 (Washington: PhRMA, July 1998, and Annual Survey Report: 198385 (Washington: PhRMA, 1986; and U.S. Bureau of the Census, Census of Manufactures: 1992, and Annual Surveys of Manufactures, various years.NOTE: Percentages were figur
21、ed using constant 1992 dollars.H E A L T H A F F A I R SS e p t e m b e r/O c t o b e r2001 220trys behavior,it has self-evident implicationsfor policy interventions aimed at reducing in-dustry prices and profits.NOTES1.H.G.Grabowski and J.M.Vernon,“A New Lookat the Returns and Risks to Pharmaceutic
22、alR&D,”Management Science(July 1990: 804821.2.See C.P.Himmelberg and B.C.Petersen,“R&Dand Internal Finance: A Panel Study of SmallFirms in High-Tech Industries,”Review of Econom-ics and Statistics(February 1994:3851;W.W.McCutchen Jr.,“Estimating the Impact of theR&D Tax Credit on Strategic Groups in thePharmaceutical Industry,”Research Poli
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 预防传染病主题班会课件
- 水肌酸产品项目规划设计方案(参考模板)
- 乡镇机关管理制度
- 吴起采油厂人执勤点工程颐园样本
- 物业员工工作计划
- 2025年微波等离子炬光谱仪项目合作计划书
- 2025年药品及医疗器械批发服务项目建议书
- 物业的服务规定规定合同(物业的服务公司的)
- 博物馆解决方案方案
- 2025年试验机械相关检测仪器合作协议书
- 2023年小学数学必背定义和公式
- 2023年四川省宜宾市全科医学专业实践技能测试卷(含答案)
- 电梯井道脚手架施工方案
- 兴平市生活垃圾焚烧发电项目环评报告
- 初中数学浙教版九年级上册第4章 相似三角形4.3 相似三角形 全国公开课一等奖
- 主令电器(课用)课件
- DLT 5066-2010 水电站水力机械辅助设备系统设计技术规定
- 湘少版英语六年级下册全册教案
- 测绘生产困难类别细则及工日定额
- 湖南省长郡中学“澄池”杯数学竞赛初赛试题(扫描版含答案)
- 消防系统施工总进度计划
评论
0/150
提交评论